ESTRO 2024 - Abstract Book

S2391

Clinical - Urology

ESTRO 2024

Conclusion:

Hypofractionated postoperative radiotherapy in prostate cancer is a safe treatment with excellent acute and late GU and GI toxicity profile and very good biochemical control maintaining quality of life. Longer follow-up is needed to confirm chronic toxicity, QoL and oncologic outcomes.

Keywords: Hypofractionated, postoperative, prostate

References:

Siepe G, Buwenge M, Nguyen NP, Macchia G, Deodato F, Cilla S, et al. Postoperative hypofractionated radiation therapy in prostate Carcinoma: A systematic review. Vol. 38, Anticancer Research. 2018.

Chin S, Fatimilehin A, Walshaw R, Argarwal A, Mistry H, Elliott T, et al. Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure. Int J Radiat Oncol Biol Phys. 2020;107(2):288 – 96. Is hypofractionation acceptable for prostate bed radiotherapy? Fernando López Campos M.D., Gemma Sancho Pardo M.D., Xavier Maldonado Pijoan M.D., Ph.D. , Thomas Zilli M.D., Ph.D. , Felipe Couñago Lorenzo M.D., Ph.D. , Asunción Hervás Morón M.D., Ph.D. Urologíc Oncology: Seminars and Original Investigations, 39 (6), 2021: 346-350

1099

Digital Poster

Salvage radiotherapy of recurrent prostate cancer after PSMA PET/MRI and PET/CT

Ingerid S Knudtsen 1 , Bendik S Abrahamsen 1 , Kirsten M Selnæs 2 , Sverre Langørgen 2 , Thomas M Keil 2 , Håkon Johansen 2 , Miguel J Castillejo 3 , Trond V Bogsrud 3,4,5 , Erling J Aarsæther 6,7 , Hege S Haugnes 8,7 , Torgrim Tandstad 9,10 , Mattijs Elschot 1,2 , Tone F Bathen 1,2 1 NTNU, Department of Circulation and Medical Imaging, Trondheim, Norway. 2 St Olavs Hospital, Department of Radiology and Nuclear Medicine, Trondheim, Norway. 3 University Hospital of North Norway, PET Imaging Centre, Tromsø, Norway. 4 Aarhus University Hospital, PET-Centre, Aarhus, Denmark. 5 Oslo University Hospital, Department of Nuclear Medicine, Oslo, Norway. 6 University Hospital of North Norway, Department of Urology, Tromsø, Norway. 7 The Arctic University of Norway, Department of Clinical Medicine, Tromsø, Norway. 8 University Hospital of North Norway, Department of Oncology, Tromsø, Norway. 9 St Olavs Hospital, Cancer Clinic, Trondheim, Norway. 10 NTNU, Department of Clinical and Molecular Medicine, Trondheim, Norway

Purpose/Objective:

PET imaging with tracers targeting the prostate specific membrane antigen (PSMA), PSMA PET, has high sensitivity and specificity for detection of recurrent prostate cancer compared to standard modalities as MRI, CT and bone scintigraphy and is now recommended by clinical guidelines. It is unclear whether the examination will lead to